Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7839404 | 0.80 | ALDH1A1 (0.36) | HPGDTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7838779 | 0.73 | ACHE (0.36) | ALDH1A1LMNA | |
| SCHEMBL14479289 | 0.69 | CYP3A4 (0.39) | HPGDTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL13929107 | 0.67 | HPGD (0.35) | HPGDTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7839894 | 0.66 | HPGD (0.35) | HPGDTSHRKMT2AALDH1A1LMNA | |
| SCHEMBL275642 | 0.65 | HPGD (0.40) | HPGDTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL278953 | 0.65 | HPGD (0.40) | HPGDTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL8043508 | 0.65 | LMNA (0.41) | HPGDMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL279006 | 0.65 | HPGD (0.34) | HPGDTSHRKMT2AALDH1A1 | |
| SCHEMBL7841968 | 0.64 | KMT2A (0.42) | HPGDTSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-7928233-B2 | Spiroindolinone pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100204257-A1 | SPIROINDOLINONE PYRIDINE DERIVATIVES | CHEN LI | 2010-08-12 | — | — | US | disclosed |
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CHEN LI | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190814-A1 | SPIROINDOLINONE DERIVATIVE PRODRUGS | CCNE1, CCNE2, CCND1 | HPGD 255/4885TSHR 1129/4885MEN1 951/4885 |
| US-20100204257-A1 | SPIROINDOLINONE PYRIDINE DERIVATIVES | RB1, KRAS, WEE1 | HPGD 1255/4885TSHR 1182/4885MEN1 904/4885 |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | HPGD 1763/4885TSHR 1695/4885MEN1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.